Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Adv Mater. 2016 Nov 25;29(4):10.1002/adma.201604043. doi: 10.1002/adma.201604043

Figure 2.

Figure 2

In vitro anticoagulant capacity of the TR-HAHP hydrogel. (a) In vitro analysis of the activated thromboplatin time (aPTT) of untreated (HA), HP treated, non-crosslinked and crosslinked TR-HAHP or NR-HAHP treated plasma. (b) Prothrombin time (PT) tests of plasma incubated with HA, HP, TR-HAHP and NR-HAHP hydrogels. (c) Thrombin clotting time (TCT) of plasma added with various hydrogels. (d) Concentations of F1+2 fragment after each incubation period (3h) indicates only the TR-HAHP hydrogel can effectively suppress the thrombin generation during the second incubation. Error bars indicate s.d. (n=3).